Modeling the TB/HIV-1 Co-Infection and the Effects of Its Treatment

Mathematical Population Studies

Volumn 17, Issue 1, 2010, Pages 12-64

  Magombedze, Gesham ^a   Garira, Winston ^a   Mwenje, Eddie ^a  

^a NATIONAL UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Zimbabwe)

Author keywords

AIDS; Co infection; Highly active anti retroviral therapy (HAART); Mycobacterium tuberculosis; TB chemotherapy

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CHEMOTHERAPY; DISEASE TREATMENT; DRUG PRESCRIBING; HUMAN IMMUNODEFICIENCY VIRUS; MODELING; TUBERCULOSIS;

HUMAN IMMUNODEFICIENCY VIRUS; MYCOBACTERIUM TUBERCULOSIS;

EID: 75849154956     PISSN: 08898480     EISSN: 1547724X     Source Type: Journal    
DOI: 10.1080/08898480903467241     Document Type: Article

References (61)

1. Aquaro, S., Calio, R., Balzarini, J., Bellocchi, M.C., Garaci, E., and Perno, C.F. (2002). Macrophages and HIV infection: therapeutical approaches toward the strategic virus reservoir. Antiviral Research, 55: 209-225.
2. Aquaro, S., Svicher, V., Schols, D., Pollicita, M., Antino, A., Bulzarini, J., et al. (2006). Mechanisms underlying activity of antiretroviral drugs in HIV-1 infected macro- phages: New therapeutic strategies. Journal of Leukocyte and Biology, 80: 1-8.
3. Badley, A.D., Dockrell, D., Simpson, M., Schut, R., Lynch, D.H., Leibson, P. et al. (1997). Macrophage-dependent apoptosis of CD4+ T lyphocytes from HIV-infected individuals mediated by FasL and Tumor Necrosis Factor. Journal of Experimental Medicine, 185: 55-64.
4. Bean, A.D., Roach, D.R., Briscoe, H., France, M.P., Kapner, H., Sedgwick, J.D., et al. (1999). Structural deficiencies in granuloma formation in TNF gene-targeted mice underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis infection, which is not compensated for by Lymphotoxin. Journal of Immunology, 162: 3504-3511.
5. Briz, V., Poveda, E., and Soriano, V. (2006). HIV entry inhibitors: Mechanisms of action and resistance pathways. Journal of Antimicrobial Chemotherapy, 57: 619-627.
6. Burman, W.J. and Jones, B.E. (2001). Treatment of HIV-related tuberculosis in the era of effective antiretroviral therapy. American Journal of Respiratory and Critical Care Medicine, 164: 7-12.
7. Burman, W., Benator, D., Vernon, A., Khan, A., Jones, B., Silva, C., et al. (2005). Acquired Rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis. American Journal of Respiratory and Critical Care Medicine, 173: 350-356.
8. Burger, D.M., Agarwala, S., Child, M., Been-Tiktak, A., Wang, Y., and Bertz, R. (2006). Effect of Rifampin on steady-state pharmacokinetics of Atazanavir with Ritonavir in healthy volunteers. Antimicrobial Agents and Chemotherapy, 50: 3336-3342.
9. Castillo-Chavez, C., Feng, Z., and Huang, W. (2002). On the computation R0 its role on global stability. Mathematical approaches for emerging and re-emerging infectious diseases. IMA, 125: 229-250.
10. Diekmann, O., Heesterbeek, J.P., and Metz, J.J. (1990). On the definition and computation of the basic reproduction ratio R0 in models for infectious diseases in heterogeneous populations. Journal of Mathematical Biology, 28: 365-382.
11. Droste, J.H., Verweij-van Wissen, C.M., Kearney, B.P., Buffels, R., van Horssen, P.J., Herkster, Y.A., et al. (2005). Pharmacokinetic study of Tenofovir Disoproxil Fumerate combined with Rifampin in healthy volunteers. Antimicrobial Agents and Chemotherapy, 49(2): 680-684.
12. Ernst, W.A., Thoma-Uszynski, S., Teitelbaum, R., Ko, C., Hanson, C., Clayberger, A.M., et al. (2000). Granulysin, a T cell product, kills bacteria by altering membrane permeability. Journal of Immunology, 165: 7102-7108.
13. Flynn, J.L., Goldstein, M.M., Chan, J., Frieblod, K.J., Pfeffer, K., Lowenstein, C.J., et al. (1995). Tumor necrosis factor- is required in the protective immune response against M. tuberculosis. Infection and Immunity, 2: 561-572.
14. Flynn, J.L. and Chan, J. (2001). Tuberculosis: Latency and reactivation: Minireview. Infection and Immunity, 69: 4195-4201.
15. Flynn, J.L. (2004). Immunology of tuberculosis and implications in vaccine developments. Tuberculosis, 84: 93-101.
16. Garira, W., Musekwa, S.D., and Shiri, T. (2005). Optimal control of combined therapy in a single strain HIV-1 model. Electronic Journal of Differential Equations, 52: 1-22.
17. Gurumurthy, P., Ramachandran, G., Kumar, A.H., Rajasekaran, S., Padmapriyadarsini, C., Swaminathan, S., et al. (2004). Decreased bioavailability of Rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease. Antimicrobial Agents and Chemotherapy, 48: 4473-4475.
18. Hershfield, E. (1999). Tuberculosis: 9. Treatment. Clinical Methods and Application Journal, 161: 194-199.
19. Honda, Y., Rogers, L., Nakata, K., Zhao, B., Pine, R., Nakai, Y., et al. (1998). Type I Interferon induces inhibitory 16-kD CCAAT/Enhancer binding protein (C/EBP), repressing the HIV-1 long terminal repeat in macrophages: Pulmonary tuberculosis alters C/EBP expression, enhancing HIV-1 replication. Journal of Experimental Medicine, 188: 1255-1265.
20. Hoshino, Y., Nakata, K., Hoshino, S., Honda Y., Tse, B., Shioda, T., et al. (2002). Maximal HIV-1 replication in alveolar macrophages during tuberculosis requires both lymphocytes contact and cytokines. Journal of Experimental Medicine, 195: 495-505.
21. Hoshino, Y., Tse, D.B., Rochford, G., Prabhakar, S., Hoshino, S., Chitkara, N., et al. (2004). Mycobacterium tuberculosis-induced CXCR4 and chemokine expression leads to preferential X4 HIV-1 replication in human macrophages. Journal of Immunology, 172: 6251-6258.
22. Howe, M. (1993). Aids Information Newsletter, 202: 203-206.
23. Janeway, A.C., Travers, P., Walport, M., and Shlomchik, J.M. (2005). Immuno Biology: The Immune System in Health and Disease (6th Edition). New York: Garland Science Publishing.
24. Juffermans, N.P., Paxton, W.A., Dekkers, P.P., Verbon, A., Jonge, E., Speelman, P., et al. (2000). Up-regulation of HIV coreceptors CXCR4 and CCR5 on CD4+ T cells during human endotoxemia and after stimulation with (myco)bacterial antigens: The role of cytokines. Blood, 96: 2649-2654.
25. Kaplan, D. and Seig, S. (1998). Role of the Fas/Fas ligand apoptotic pathway in human immunodeficiency virus type 1 disease. Journal of Virology, 72: 6279-6282.
26. Kirschner, D. (1996). Using mathematics to understanding HIV immune dynamics. Notices of the Aims, 43: 191-202.
27. Kirschner, D.E. and Wedd, G.F. (1997). A mathematical model of combined drug therapy of HIV infection. Journal of Theoretical Medicine, 1: 25-34.
28. Kirschner, D. (1999). Dynamics of co-infection with M. tuberculosis and HIV-1. Theoretical Population Biology, 55: 94-109.
29. Klenerman, P., Wu, Y., and Philips, R. (2002). HIV: current opinion on escapology. Current Opinion in Microbiology, 5: 408-413.
30. Kulkut, G. (2006). Lecture of tuberculosis. Retreived April 20, 2006, from http://tuberculosis.net.
31. Langenkamp, A., Messi, M., Lanzavecchia, A., and Sallusto, F. (2000). Kinetics of dendritic cell activation: Impact on printing of Th1, Th2 and non-polarised T cells. Immunology, 1: 311.
32. Lever, N.L. (1996). The Molecular Biology of HIV/AIDS. New York: John Wiley and Sons.
33. Magnani, M., Balestra, E., Fraternale, A., Aquaro, S., Piardini, M., Cervasi, B., et al. (2003). Drug-loaded red blood cell-mediated clearance of HIV-1 macrophage reservoir by selective inhibition of STAT 1 expression. Journal of Leukocyte and Biology, 74: 764-771.
34. Magombedze, G., Garira, W., and Mwenje, E. (2006). Modeling the human immune response mechanisms to Mycobacterium tuberculosis infection in the lungs. Mathematical Biosciences and Engineering, 3: 661-682.
35. Magombedze, G., Garira, W., and Mwenje, E. (2006). Mathematical modeling of chemotherapy of human TB infection. Journal of Biological Systems, 14: 509-553.
36. Magombedze, G., Garira, W., and Mwenje, E. (2008). Modeling the immuno-pathogenesis of HIV-1 infection and the effect of multi-drug therapy: The role of fusion inhibitors in HAART. Mathematical Biosciences and Engineering, 5: 485-504.
37. Marino, S. and Kirschner, D. (2004). The human immune response to Mycobacterium tuberculosis in lung and lymph node. Journal of Theoretical Biology, 227: 463-486.
38. Martin-Fontecha, A., Sebastiani, S., Hopken, U.E., Uguccioni, M., Lipp, M., Lanzavecchia, A., et al. (2003). Regulation of dendritic cell migration to the draining lymph node: Impact on T lymphocyte traffic and priming. Journal of Experimental Medicine, 198: 615-621.
39. Mohan, V.P., Scanga, C.A., Yu, K., Scott, H.M., Tanaka, K.E., Tsang, E., et al. (2001). Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: Possible role for limiting pathology. Infection and Immunity, 69: 1847-1855.
40. Moore, J.P. and Doms, R.W. (2003). The entry of entry inhibitors: A fusion of science and medicine. Proceedings of the National Academy of Sciences of the United States of America, 100: 10598-10602.
41. Moyle, G. (2003). Stopping HIV fusion with enfuvirtide: The first step to extracellular HAART. Journal of Antimicrobial Chemotherapy, 51: 213-217.
42. Naresh, R. and Tripathi, A. (2005). Modeling and analysis of HIV-TB co-infection in a variable size population. Mathematical Modeling and Analysis, 10(3): 275-286.
43. Perno, C.F., Aquaro, S., Rosenwirth, B., Balestra, E., Peichi, P., Billich, A., et al. (2006). In vitro activity of late stages of the replication of HIV in chronically infected macrophages. Journal of Leukocyte and Biology, 56: 381-386.
44. Porte, C.L., Colbers, E.H., Bertz, R., Voncken, D.S., Wikstrom, K., Boeree, M., Koopmans, P.P., et al. (2004). Pharmacokinetics of adjusted-dose Lopinavir-Ritonavir combined with Rifampin in healthy volunteers. Antimicrobial Agents and Chemotherapy, 48: 1553-1560.
45. Raja, A. (2004). Immunology of tuberculosis: Review article. Indian Journal of Medicine and Respiration, 120: 213-232.
46. Raju, B., Tung, C.F., Cheng, D., Yousefzadeh, N., Condos, R., Rom, W., et al. (2001). In situ activation of helper T cells in the lung. Infection and Immunity, 69: 4790-4798.
47. Rockstroh, J.K. and Mauss, S. (2004). Clinical perspective of fusion inhibitors for treatment of HIV. Journal of Antimicrobial Chemotherapy, 53: 700-702.
48. Rossi, L., Franchetti, P., Pierige, F., Cappellacci, L., Serafini, S., Balestra, E., et al. (2007). Inhibition of HIV-1 replication in macrophages by a heterodinucleotide of lamivudine and tenofovir. Journal of Antimicrobial Chemotherapy, 59: 666-675.
49. Sahai, J., Gallicano, K., Swick, L., Tailor, S., Garber, G., Seguin, I., et al. (1997). Reduced plasma concentration of antituberculosis drugs in patients with HIV infection. Annual International Medicine, 127: 289-293.
50. Segovia-Juarez, J.L., Ganguli, S., and Kirschner, D. (2004). Identifying control mechanisms of granuloma formation during M. tuberculosis infection using an agent-based model. Journal of Theoretical Biology, 231: 357-376.
51. Schluger, N.W. and Rom, W.N. (1998). The host immune response to tuberculosis: State of the art. American Journal of Respiration and Critical Care Medicine, 157: 679-691.
52. Schluger, N.W. (2001). Recent advances in our understanding of the human host responses to tuberculosis: Review. Respiratory Research, 2: 157-163.
53. Sharomi, O., Podder, C.N., Gumel, A.B., and Song, B. (2008). Mathematical analysis of the transmission dynamics of HIV/TB co-infection in the presence of treatment. Mathematical Biosciences and Engineering, 5: 145-174.
54. Shiri, T., Garira, W., and Musekwa, S.D. (2005). A two-strain HIV-1 mathematical model to assess the effects of chemotherapy on disease parameters. Mathematical Biosciences and Engineering, 2: 811-832.
55. Stenger, S., Mazzaccaro, R., Uyemura, K., Cho, S., Bames, P., Rosat, J. et al. (1997). Differential effects of cytolytic T cell subsets on intracellular infection. Science, 276: 1684-1687.
56. Sud, D., Bigbee, C., Flynn, J.L., and Kirschner, D.E. (2006). Contribution of CD8+ T cells of Mycobacterium tuberculosis infection. Journal of Immunology, 176: 4296-4314.
57. Weiden, M., Tanaka, N., Qiao, Y., Zhao, B.Y., Honda, Y., Nakata, K., et al. (2000). Differentiation of monocytes to macrophages switches the Mycobacterium tuberculosis effect on HIV-1 replication from stimulation to inhibition: Modulation of interferon response and CCAAT/Enhancer binding protein expression. Journal of Immunology, 165: 2028-2039.
58. Wigginton, J.E. and Kirschner, D. (2001). A model to predict cell mediated immune regulatory mechanisms during human infection with Mycobacterium tuberculosis. Journal of Immunology, 166: 1951.
59. Wodarz, D. and Nowak, M.A. (2000). Immune responses and viral phenotype: Do replication rate and cytopathicity influence virus load? Journal of Theoretical Medicine, 2: 113-127.
60. Wodarz, D., Sierro, S., and Klenerman, P. (2007). Dynamics of killer T cell inflation in viral infections. Journal of Royal Society Interface, 4: 533-543.
61. Yi, Y., Isaacs, S.N., Williams, D.A., Frank, I., Schols, D., De Clercq, E., et al. (1999). Role of CXCR4 in cell-cell fusion and infection of monocyte derived macrophages by primary human immunodeficiency virus type 1 (HIV-1) strains: Two distinct mechanisms of HIV-1 dual tropism. Journal of Virology, 73: 7117-7125.